NASDAQ:STML - StemlineTherapeutics Stock Price, Price Target & More

$17.20 -0.10 (-0.58 %)
(As of 04/20/2018 08:36 AM ET)
Previous Close$17.30
Today's Range$17.00 - $17.60
52-Week Range$7.30 - $18.75
Volume152,200 shs
Average Volume330,433 shs
Market Capitalization$522.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.07

About StemlineTherapeutics (NASDAQ:STML)

StemlineTherapeutics logoStemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311

Debt

Debt-to-Equity RatioN/A
Current Ratio2.63%
Quick Ratio2.63%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$900,000.00
Price / Sales577.35
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book10.62

Profitability

EPS (Most Recent Fiscal Year)($2.94)
Net Income$-67,820,000.00
Net Margins-4,689.63%
Return on Equity-94.70%
Return on Assets-77.89%

Miscellaneous

Employees37
Outstanding Shares30,210,000

How to Become a New Pot Stock Millionaire

StemlineTherapeutics (NASDAQ:STML) Frequently Asked Questions

What is StemlineTherapeutics' stock symbol?

StemlineTherapeutics trades on the NASDAQ under the ticker symbol "STML."

How were StemlineTherapeutics' earnings last quarter?

StemlineTherapeutics Inc. (NASDAQ:STML) released its earnings results on Friday, March, 16th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.26. StemlineTherapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%. View StemlineTherapeutics' Earnings History.

When is StemlineTherapeutics' next earnings date?

StemlineTherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for StemlineTherapeutics.

What price target have analysts set for STML?

4 Wall Street analysts have issued twelve-month price targets for StemlineTherapeutics' stock. Their predictions range from $16.00 to $40.00. On average, they anticipate StemlineTherapeutics' stock price to reach $31.3333 in the next twelve months. View Analyst Ratings for StemlineTherapeutics.

What are Wall Street analysts saying about StemlineTherapeutics stock?

Here are some recent quotes from research analysts about StemlineTherapeutics stock:
  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (3/23/2018)
  • 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
  • 3. Cowen Inc analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)

Are investors shorting StemlineTherapeutics?

StemlineTherapeutics saw a increase in short interest in March. As of March 29th, there was short interest totalling 2,316,217 shares, an increase of 46.8% from the March 15th total of 1,577,965 shares. Based on an average daily trading volume, of 586,094 shares, the days-to-cover ratio is presently 4.0 days. Approximately 8.5% of the company's shares are sold short.

Who are some of StemlineTherapeutics' key competitors?

Who are StemlineTherapeutics' key executives?

StemlineTherapeutics' management team includes the folowing people:
  • Dr. Ivan Bergstein, Founder, Chairman, CEO & Pres (Age 52)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 58)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 53)
  • Dr. Eric K. Rowinsky, Consultant (Age 61)

Has StemlineTherapeutics been receiving favorable news coverage?

Media stories about STML stock have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. StemlineTherapeutics earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of StemlineTherapeutics?

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is StemlineTherapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $17.20.

How big of a company is StemlineTherapeutics?

StemlineTherapeutics has a market capitalization of $522.64 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. StemlineTherapeutics employs 37 workers across the globe.

How can I contact StemlineTherapeutics?

StemlineTherapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]


MarketBeat Community Rating for StemlineTherapeutics (STML)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about StemlineTherapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

StemlineTherapeutics (NASDAQ:STML) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for StemlineTherapeutics in the last 12 months. Their average twelve-month price target is $31.3333, suggesting that the stock has a possible upside of 82.17%. The high price target for STML is $40.00 and the low price target for STML is $16.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.3333$31.3333$33.75$32.60
Price Target Upside: 82.17% upside123.01% upside115.65% upside232.65% upside

StemlineTherapeutics (NASDAQ:STML) Consensus Price Target History

Price Target History for StemlineTherapeutics (NASDAQ:STML)

StemlineTherapeutics (NASDAQ:STML) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018HC WainwrightInitiated CoverageBuy$38.00LowView Rating Details
10/31/2017CowenReiterated RatingBuyN/AView Rating Details
5/25/2017Jefferies GroupReiterated RatingBuy$16.00MediumView Rating Details
5/11/2017WedbushBoost Price TargetOutperform$33.00 -> $40.00HighView Rating Details
3/20/2017Ladenburg ThalmannSet Price TargetBuy$41.00MediumView Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

StemlineTherapeutics (NASDAQ:STML) Earnings History and Estimates Chart

Earnings by Quarter for StemlineTherapeutics (NASDAQ:STML)

StemlineTherapeutics (NASDAQ:STML) Earnings Estimates

2018 EPS Consensus Estimate: ($2.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.72)($0.72)($0.72)
Q3 20181($0.73)($0.73)($0.73)
Q4 20181($0.75)($0.75)($0.75)

StemlineTherapeutics (NASDAQ STML) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018N/AView Earnings Details
3/16/2018Q4 2017($0.67)($0.93)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.57)($0.68)$0.30 million$0.30 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.48)($0.66)$0.30 million$0.30 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.45)($0.67)$0.30 million$0.30 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.55)($0.56)$0.25 million$0.30 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.53)($0.56)$0.15 million$0.30 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.54)($0.52)$0.17 million$0.24 millionViewN/AView Earnings Details
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)$0.15 million$0.21 millionViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)$0.10 million$0.21 millionViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)$0.10 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q1($0.4540)($0.46)$0.09 million$0.12 millionViewN/AView Earnings Details
3/13/2015($0.60)($0.53)$0.07 million$0.12 millionViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)$0.07 million$0.07 millionViewN/AView Earnings Details
8/14/2014($0.71)($0.47)$0.07 million$0.07 millionViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.0710 million$0.0710 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.45)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.90)ViewN/AView Earnings Details
4/1/2013Q4 2012($0.38)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

StemlineTherapeutics (NASDAQ:STML) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

StemlineTherapeutics (NASDAQ STML) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 49.87%
Insider Trading History for StemlineTherapeutics (NASDAQ:STML)
Insider Trading History for StemlineTherapeutics (NASDAQ:STML)

StemlineTherapeutics (NASDAQ STML) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Kenneth HobermanCOOSell29,987$17.14$513,977.18View SEC Filing  
3/12/2018David GioncoInsiderSell9,183$17.38$159,600.54View SEC Filing  
3/12/2018Ivan BergsteinCEOSell37,857$17.34$656,440.38View SEC Filing  
3/7/2018David GioncoInsiderSell1,413$16.56$23,399.28View SEC Filing  
3/7/2018Ivan BergsteinCEOSell6,797$16.56$112,558.32View SEC Filing  
3/7/2018Kenneth HobermanCOOSell3,027$16.55$50,096.85View SEC Filing  
2/27/2018David GioncoInsiderSell8,984$17.43$156,591.12View SEC Filing  
2/27/2018Ivan BergsteinCEOSell24,183$17.42$421,267.86View SEC Filing  
2/27/2018Kenneth HobermanCOOSell11,026$17.43$192,183.18View SEC Filing  
2/15/2018Ivan BergsteinCEOSell3,820$15.80$60,356.00View SEC Filing  
2/15/2018Kenneth HobermanCOOSell1,851$15.67$29,005.17View SEC Filing  
1/17/2018David GioncoInsiderSell4,250$13.43$57,077.50View SEC Filing  
1/8/2018Kenneth HobermanCOOSell14,040$13.93$195,577.20View SEC Filing  
12/18/2017Kenneth HobermanCOOSell11,983$14.18$169,918.94View SEC Filing  
12/15/2017Kenneth HobermanCOOSell11,943$14.18$169,351.74View SEC Filing  
2/28/2017David GioncoInsiderSell6,486$6.99$45,337.14View SEC Filing  
2/28/2017Ivan BergsteinCEOSell17,980$6.99$125,680.20View SEC Filing  
2/28/2017Kenneth HobermanCOOSell8,027$6.99$56,108.73View SEC Filing  
2/27/2017David GioncoCAOSell3,500$6.97$24,395.00View SEC Filing  
2/27/2017Ivan BergsteinCEOSell7,500$6.97$52,275.00View SEC Filing  
2/27/2017Kenneth HobermanCOOSell4,000$6.97$27,880.00View SEC Filing  
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36106,467View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.581,846,128View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08297,392View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.9435,244View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.001,926,826View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

StemlineTherapeutics (NASDAQ STML) News Headlines

Source:
DateHeadline
Zacks Investment Research Downgrades StemlineTherapeutics (STML) to SellZacks Investment Research Downgrades StemlineTherapeutics (STML) to Sell
www.americanbankingnews.com - April 17 at 6:29 PM
Form 8-K STEMLINE THERAPEUTICS For: Apr 16Form 8-K STEMLINE THERAPEUTICS For: Apr 16
www.streetinsider.com - April 17 at 9:07 AM
StemlineTherapeutics (STML) Upgraded at BidaskClubStemlineTherapeutics (STML) Upgraded at BidaskClub
www.americanbankingnews.com - April 16 at 11:29 PM
Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of ...Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of ...
globenewswire.com - April 16 at 4:58 PM
BRIEF-Stemline Therapeutics Expands Board Of Directors With Appointment Of Darren ClineBRIEF-Stemline Therapeutics Expands Board Of Directors With Appointment Of Darren Cline
www.reuters.com - April 16 at 8:44 AM
Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren ClineStemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline
feeds.benzinga.com - April 16 at 7:46 AM
StemlineTherapeutics Inc. (STML) Short Interest Up 46.8% in MarchStemlineTherapeutics Inc. (STML) Short Interest Up 46.8% in March
www.americanbankingnews.com - April 14 at 2:29 AM
StemlineTherapeutics (STML) Upgraded by BidaskClub to BuyStemlineTherapeutics (STML) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - April 12 at 10:45 AM
HC Wainwright Reiterates "$34.00" Price Target for StemlineTherapeutics (STML)HC Wainwright Reiterates "$34.00" Price Target for StemlineTherapeutics (STML)
www.americanbankingnews.com - April 11 at 11:52 PM
ValuEngine Lowers StemlineTherapeutics (STML) to SellValuEngine Lowers StemlineTherapeutics (STML) to Sell
www.americanbankingnews.com - April 11 at 3:58 PM
Zacks: Analysts Expect StemlineTherapeutics Inc. (STML) Will Announce Earnings of -$0.70 Per ShareZacks: Analysts Expect StemlineTherapeutics Inc. (STML) Will Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 10 at 1:22 PM
HC Wainwright Begins Coverage on StemlineTherapeutics (STML)HC Wainwright Begins Coverage on StemlineTherapeutics (STML)
www.americanbankingnews.com - April 6 at 10:47 AM
Stemline Therapeutics (STML) Begins Rolling BLA Submission for SL-401Stemline Therapeutics (STML) Begins Rolling BLA Submission for SL-401
www.streetinsider.com - April 5 at 10:51 AM
Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
finance.yahoo.com - April 5 at 10:51 AM
StemlineTherapeutics Inc. (STML) Receives Average Recommendation of "Buy" from BrokeragesStemlineTherapeutics Inc. (STML) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 5 at 3:24 AM
StemlineTherapeutics (STML) Upgraded at ValuEngineStemlineTherapeutics (STML) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:00 AM
Stemline Therapeutics (STML) Upgraded to "Buy" at BidaskClubStemline Therapeutics (STML) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 5:40 PM
Stemline Therapeutics (STML) Rating Lowered to Hold at BidaskClubStemline Therapeutics (STML) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 29 at 6:54 PM
Stemline Therapeutics (STML) Upgraded to "Hold" by BidaskClubStemline Therapeutics (STML) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
Stemline Therapeutics (STML) Upgraded by ValuEngine to "Hold"Stemline Therapeutics (STML) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 23 at 8:28 PM
Stemline Therapeutics Inc Stock Investors Are Betting, Not InvestingStemline Therapeutics Inc Stock Investors Are Betting, Not Investing
investorplace.com - March 23 at 6:33 PM
Stemline Therapeutics (STML) Lowered to "Sell" at Zacks Investment ResearchStemline Therapeutics (STML) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 3:07 PM
Stemline Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($0.72) Per Share (STML)Stemline Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($0.72) Per Share (STML)
www.americanbankingnews.com - March 22 at 8:12 AM
Stemline Therapeutics (STML) Cut to "Hold" at BidaskClubStemline Therapeutics (STML) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 21 at 10:36 PM
Stemline Therapeutics Inc Expected to Post FY2022 Earnings of $2.29 Per Share (STML)Stemline Therapeutics Inc Expected to Post FY2022 Earnings of $2.29 Per Share (STML)
www.americanbankingnews.com - March 21 at 4:40 PM
HC Wainwright Reiterates "$38.00" Price Target for Stemline Therapeutics (STML)HC Wainwright Reiterates "$38.00" Price Target for Stemline Therapeutics (STML)
www.americanbankingnews.com - March 19 at 5:02 PM
Stemline Therapeutics (STML) Upgraded by BidaskClub to BuyStemline Therapeutics (STML) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 18 at 4:24 PM
Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 18 at 8:46 AM
Stemline Therapeutics Reports Fourth Quarter 2017 Financial ResultsStemline Therapeutics Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 16 at 8:55 AM
Stemline Therapeutics reports 4Q lossStemline Therapeutics reports 4Q loss
finance.yahoo.com - March 16 at 8:55 AM
Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 29,987 SharesStemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 29,987 Shares
www.americanbankingnews.com - March 14 at 11:12 PM
Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 37,857 SharesStemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 37,857 Shares
www.americanbankingnews.com - March 14 at 10:41 PM
Stemline Therapeutics Inc (STML) Insider Sells $159,600.54 in StockStemline Therapeutics Inc (STML) Insider Sells $159,600.54 in Stock
www.americanbankingnews.com - March 14 at 10:41 PM
Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)
finance.yahoo.com - March 14 at 9:23 AM
ValuEngine Downgrades Stemline Therapeutics (STML) to SellValuEngine Downgrades Stemline Therapeutics (STML) to Sell
www.americanbankingnews.com - March 13 at 10:19 PM
Stemline Therapeutics (STML) Cut to Sell at ValuEngineStemline Therapeutics (STML) Cut to Sell at ValuEngine
www.americanbankingnews.com - March 11 at 9:02 PM
Stemline Therapeutics Inc (STML) Given Average Rating of "Hold" by BrokeragesStemline Therapeutics Inc (STML) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 11 at 4:29 AM
Kenneth Hoberman Sells 3,027 Shares of Stemline Therapeutics Inc (STML) StockKenneth Hoberman Sells 3,027 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - March 10 at 4:21 AM
Ivan Bergstein Sells 6,797 Shares of Stemline Therapeutics Inc (STML) StockIvan Bergstein Sells 6,797 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - March 10 at 4:20 AM
Stemline Therapeutics Inc (STML) Insider Sells $23,399.28 in StockStemline Therapeutics Inc (STML) Insider Sells $23,399.28 in Stock
www.americanbankingnews.com - March 10 at 4:20 AM
Stemline Therapeutics (STML) Set to Announce Earnings on WednesdayStemline Therapeutics (STML) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM
Contrasting Spring Bank Pharmaceuticals (SBPH) and Stemline Therapeutics (STML)Contrasting Spring Bank Pharmaceuticals (SBPH) and Stemline Therapeutics (STML)
www.americanbankingnews.com - March 2 at 1:39 PM
Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 24,183 SharesStemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 24,183 Shares
www.americanbankingnews.com - March 1 at 12:38 AM
Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 11,026 SharesStemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 11,026 Shares
www.americanbankingnews.com - March 1 at 12:38 AM
Stemline Therapeutics Inc (STML) Insider David Gionco Sells 8,984 SharesStemline Therapeutics Inc (STML) Insider David Gionco Sells 8,984 Shares
www.americanbankingnews.com - March 1 at 12:38 AM
Kenneth Hoberman Sells 1,851 Shares of Stemline Therapeutics Inc (STML) StockKenneth Hoberman Sells 1,851 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - February 17 at 12:14 AM
Ivan Bergstein Sells 3,820 Shares of Stemline Therapeutics Inc (STML) StockIvan Bergstein Sells 3,820 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - February 17 at 12:14 AM
Zacks Investment Research Lowers Stemline Therapeutics (STML) to SellZacks Investment Research Lowers Stemline Therapeutics (STML) to Sell
www.americanbankingnews.com - February 15 at 2:08 PM
Stemline Therapeutics Inc (STML) Receives Consensus Rating of "Buy" from AnalystsStemline Therapeutics Inc (STML) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 14 at 3:34 AM
Stemline Therapeutics (STML) Downgraded by Zacks Investment ResearchStemline Therapeutics (STML) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 1:04 PM

SEC Filings

StemlineTherapeutics (NASDAQ:STML) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

StemlineTherapeutics (NASDAQ:STML) Income Statement, Balance Sheet and Cash Flow Statement

Chart

StemlineTherapeutics (NASDAQ STML) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.